Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.420
-0.090 (-2.56%)
At close: Jan 16, 2026, 4:00 PM EST
3.470
+0.050 (1.46%)
After-hours: Jan 16, 2026, 7:15 PM EST
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$788,351
Market Cap
38.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | 3 | 14.29% |
| Dec 31, 2023 | 21 | -2 | -8.70% |
| Dec 31, 2022 | 23 | 7 | 43.75% |
| Dec 31, 2021 | 16 | 1 | 6.67% |
| Dec 31, 2020 | 15 | 8 | 114.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LTRN News
- 7 days ago - Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - Business Wire
- 6 weeks ago - Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Business Wire
- 2 months ago - Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript - Seeking Alpha
- 2 months ago - Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET - Business Wire
- 2 months ago - Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - Business Wire
- 2 months ago - Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - Business Wire